BIOMAT Database Logo BIOMAT Database Logo

[The clinical efficacy of antithrombin III concentrate in infections complicated by DIC]. 1985

H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D018805 Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK. Bloodstream Infection,Pyaemia,Pyemia,Pyohemia,Blood Poisoning,Poisoning, Blood,Septicemia,Severe Sepsis,Blood Poisonings,Bloodstream Infections,Infection, Bloodstream,Poisonings, Blood,Pyaemias,Pyemias,Pyohemias,Sepsis, Severe,Septicemias

Related Publications

H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
Substitution therapy with an antithrombin III concentrate in shock and DIC.
August 1982, Thrombosis research,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
Antithrombin III concentrate in the treatment of DIC: a retrospective follow-up study.
November 1994, The Netherlands journal of medicine,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
[Fundamental studies on the management of disseminated intravascular coagulation (DIC) with antithrombin III (AT-III) concentrate].
April 1985, Nihon Sanka Fujinka Gakkai zasshi,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
Antithrombin III immunoelectrophoretic pattern in DIC.
August 1978, Thrombosis research,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
A pasteurized antithrombin III concentrate for clinical use.
January 1985, Vox sanguinis,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
Safety of antithrombin III concentrate.
August 1990, Blood,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients.
August 1984, Thrombosis research,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.
September 1989, The American journal of medicine,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
The pregnant antithrombin III deficient patient: management without antithrombin III concentrate.
January 1992, Thrombosis research,
H Kobayashi, and S Kawai, and H Oshitani, and S Tamakuma, and H Hayasaka, and M Akiyama, and T Nakamura, and I Hashimoto, and Y Sawada, and K Takebe
Treatment of DIC with antithrombin III concentrates.
January 1983, Bibliotheca haematologica,
Copied contents to your clipboard!